The U.S. Food and Drug Administration (FDA) has mandated updates to the labeling of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to include warnings regarding a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION).
This regulatory action follows a comprehensive federal review of clinical trial, animal, and postmarketing data.
GLP-1 RAs Show Higher Incidence of NAION Events
- NAION is a condition involving sudden, painless vision loss caused by restricted blood flow to the optic nerve.
- The FDA’s review of 126 clinical trials involving over 134,000 patients found a higher incidence rate of NAION events in those using GLP-1 RAs compared to those on other medications.
- If you are currently prescribed a GLP-1 RA, do not discontinue your medication without first speaking to your healthcare provider, as sudden cessation can impact your metabolic health.
FDA Meta-Analysis Findings
The regulatory decision follows a rigorous meta-analysis conducted by the FDA to evaluate the incidence of NAION across the GLP-1 RA drug class. Researchers examined 134,253 patients, encompassing 288,879 person-years (PY) of exposure. The analysis identified 15 probable NAION events: 10 occurring in patients treated with GLP-1 RAs and 5 in the placebo-treated group.
The data demonstrated an incidence rate of 6.4 events per 100,000 PY for GLP-1 RA users, compared to 3.8 events per 100,000 PY in the comparator group. While the FDA noted that reports through the Adverse Event Monitoring System (AEMS) were difficult to interpret due to overlapping risk factors, the consistency of these findings across clinical trials necessitated the updated safety disclosures.
Real-World Evidence from the Sentinel Network
To further validate these findings, the FDA conducted a retrospective cohort study using the Sentinel Real-World Evidence Data Enterprise (RWE-DE). This study compared NAION incidence among adults with type 2 diabetes who initiated GLP-1 RAs, SGLT-2 inhibitors, or DPP-4 inhibitors between 2019 and 2024. The results revealed no statistically significant increase in risk when comparing GLP-1 RAs to SGLT-2 inhibitors, with a hazard ratio of 1.19.
However, when compared to DPP-4 inhibitors, the data indicated an increased risk for NAION, with a hazard ratio of 1.43. These results align with previously published observational research, including the study by Hathaway et al. (2024), which prompted the initial investigation into the relationship between these medications and optic nerve health.
| Medication Class | Incidence per 100,000 PY |
|---|---|
| GLP-1 Receptor Agonists | 30–32 |
| SGLT-2 Inhibitors | 31 |
| DPP-4 Inhibitors | 26 |
Monitor for Sudden Vision Loss and Risk Factors
NAION is a rare but serious condition. Patients with pre-existing cardiovascular disease, hypertension, or diabetes are at an elevated baseline risk for ischemic events. It is critical that patients monitor for sudden, painless loss of vision in one eye, which is the hallmark symptom of NAION.
If you experience any sudden changes in your visual field, you should seek an immediate evaluation by an ophthalmologist or emergency medical professional.
While the FDA has not identified a biological mechanism in animal models explaining how GLP-1 RAs might trigger NAION, the association observed in clinical and observational data is sufficient to warrant heightened vigilance. Always discuss your medical history, including any prior eye health issues, with your prescribing physician before starting or continuing GLP-1 RA therapy.
The FDA Reviewed All Marketed GLP-1 RA Products
The FDA’s assessment included a review of all currently marketed GLP-1 RA products.
